Sign In
NewsRadar

Covagen (acquired by Cilag)

Covagen develops protein therapeutics called Fynomers.

They are aimed at the treatment of inflammatory diseases and cancer by using its protein engineering technology.


• Show past press releases
• Edit this company

Contact Information
Address:
 
 

Phone:
Fax:
Web:
Contact:
 
 
Wagistrasse 25
Winterthurerstrasse 19
Zürich CH-8952
Switzerland
+41(0)44 732 46 60
+41(0)44 732 46 64
http://www.covagen.com
Julian Bertschinger
+41 (0) 44 635 60 33

Company Facts
Founded:
Founders:
CEO:Julian Bertschinger
CTO or technical lead:
CFO or finance director:
Head of Sales:
Head of Marketing:

Stage:
Category:Biotechnology & Healthcare
Sector:Biopharmaceuticals
Employees:
Profitability:
Funding raised:Yes
Funding sought:
Seeking Partnerships:

Non-executive Board Members

Key Customers

Key Business Partners

Key Competitors

Capital Raised
DateSizeInvestors
To view this information you must be signed in and subscribed to the online dataservice, sign in here.

To read more about the Online data service click here

Public Offerings
DateTypeExchange
No public offerings


Data


26,837
Tech investments
From our Online Data Service
17,319
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 25€24.0MInternet commerce
Apr 2€6.0MOther Computers & Electronics
Apr 2€50.0MBiotechnology
Apr 2€0.7MMedical devices
Apr 2€0.9MWireless applications
Apr 2€100.0MContent management
Apr 1€416.0MOther Biotechnology & Healthcare

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Jan 29
Yumpingo
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase





About usContact usLegal Information
Copyright 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.